Profile: TargeGen, Inc., is a biopharmaceutical company that develops small molecule kinase inhibitors for the treatment of cancer, pulmonary, ocular and certain other diseases. We develop internally discovered Jak-2 inhibitor that has demonstrated results in published pre-clinical testing. We offer TG101348, an oral, potent, and highly selective inhibitor of JAK2 for patients with myeloproliferative diseases.